Vance Fowler, MD

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Astra Zeneca
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/06/2025
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Basilea
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/20/2025
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Contrafect
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    12/01/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    EDE
    Topic:
    diagnostics
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/05/2026
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Karius
    Topic:
    diagnostics
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/01/2024
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    MedImmune
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/10/2025
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Merck
    Topic:
    UTI
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/20/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Aridis, Armata
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/04/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Astra Zeneca, Basilea
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/11/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Contrafect
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/01/2023

Pages

Return to 2024 Inova Fairfax MGR (Enduring Material): Update in S. aureus Bacteremia